Attralus Presents New Preclinical Data on AT-04 and AT-07, Pan-Amyloid Removal Therapeutics Targeting Neurodegenerative Disorders, at AD/PD 2023
April 03, 2023 07:00 ET
|
Attralus, Inc
AT-04 demonstrated sub nanomolar binding to Aβ, tau and α-synuclein fibrilsAT-04 demonstrated in vivo target engagement and binding to Aβ plaques in the brainAT-07 (AT-04 + Brain Shuttle) demonstrated...
Attralus and Ossianix Announce an Option and License Agreement using the TXP1 Brain Shuttle for Targeted Delivery of AT-04, a Pan-Amyloid Removal Therapeutic, for Neurodegenerative Disorders
November 17, 2022 07:00 ET
|
Attralus, Inc
SAN FRANCISCO and PHILADELPHIA, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with...
Alzheimer’s Patient Advocates File FOIA Seeking Answers on Discriminatory Medicare Coverage Decision
April 15, 2022 11:42 ET
|
UsAgainstAlzheimer's
Washington, D.C., April 15, 2022 (GLOBE NEWSWIRE) -- Today, UsAgainstAlzheimer’s announced their latest effort to demand answers from the Centers for Medicare and Medicare Services (CMS) about last...
NIH Awards Cerebral Amyloid Angiopathy Grant to Amydis Diagnostics
October 09, 2017 09:14 ET
|
Amydis Diagnostics, Inc.
SAN DIEGO, Oct. 09, 2017 (GLOBE NEWSWIRE) -- Amydis Diagnostics, Inc., a privately-held pharmaceutical company developing proprietary chemistry and innovative approaches for the detection of...
Amydis Diagnostics Named to San Diego Venture Group’s (SDVG) 2017 Cool Companies List
May 30, 2017 09:00 ET
|
Amydis Diagnostics, Inc.
SAN DIEGO, May 30, 2017 (GLOBE NEWSWIRE) -- Amydis Diagnostics, Inc., a preclinical stage, privately-held pharmaceutical company developing proprietary chemistry and innovative approaches to...
Amydis Diagnostics Adds Veteran Drug Development Executive and Chief Medical Officer to Management Team
May 17, 2017 09:00 ET
|
Amydis Diagnostics, Inc.
SAN DIEGO, May 17, 2017 (GLOBE NEWSWIRE) -- Amydis Diagnostics, Inc., a preclinical stage, privately-held pharmaceutical company developing proprietary chemistry and innovative approaches to...
Amydis Diagnostics Awarded NIH Grant to Further Investigate Innovative Technology for Early Detection of Alzheimer’s Disease
March 20, 2017 07:07 ET
|
Amydis Diagnostics, Inc.
SAN DIEGO, March 20, 2017 (GLOBE NEWSWIRE) -- Amydis Diagnostics, Inc., a preclinical stage, privately-held pharmaceutical company developing proprietary chemistry and innovative approaches to...
Elsevier Announces Timely New Book, "Drug Discovery Approaches for the Treatment of Neurodegenerative Disorders: Alzheimer's Disease"
November 01, 2016 04:00 ET
|
Elsevier, Inc.
CAMBRIDGE, MA--(Marketwired - November 01, 2016) - Elsevier, a world-leading provider of scientific, technical and medical information products and services, today announced the publication of Drug...
Elsevier Publishes New Book on Developing Therapeutics for Alzheimer's Disease
July 21, 2016 04:00 ET
|
Elsevier, Inc.
CAMBRIDGE, MA--(Marketwired - July 21, 2016) - Elsevier, a world-leading provider of scientific, technical and medical information products and services, today announced the publication of Developing...
Amydis Diagnostics Awarded NIA-NIH Grant to Investigate Innovative Technology for Detection of Alzheimer's Disease
September 29, 2015 09:00 ET
|
Amydis, Inc.
SAN DIEGO, Sept. 29, 2015 (GLOBE NEWSWIRE) -- Amydis Diagnostics, Inc., a preclinical stage, privately-held pharmaceutical company developing proprietary chemistry and innovative approaches to...